Fairfield Financial Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.72M Sell
4,758
-413
-8% -$141K 0.68% 32
2026
Q1
$1.82M Sell
5,171
-164
-3% -$58.5K 0.63% 33
2025
Q4
$1.75M Sell
5,335
-530
-9% -$168K 0.57% 35
2025
Q3
$1.66M Sell
5,865
-1,584
-21% -$459K 0.56% 37
2025
Q2
$2.08M Sell
7,449
-39
-0.5% -$11K 0.73% 33
2025
Q1
$2.33M Sell
7,488
-568
-7% -$168K 0.88% 27
2024
Q4
$2.1M Sell
8,056
-228
-3% -$67.6K 0.74% 24
2024
Q3
$2.67M Buy
8,284
+193
+2% +$63.1K 0.91% 22
2024
Q2
$2.53M Buy
+8,091
New +$2.38M 0.74% 24
2023
Q4
$2.1M Buy
7,294
+303
+4% +$82.6K 0.8% 28
2023
Q3
$1.88M Buy
6,991
+644
+10% +$161K 0.79% 28
2023
Q2
$1.41M Buy
6,347
+1,498
+31% +$348K 0.56% 33
2023
Q1
$1.17M Buy
4,849
+619
+15% +$152K 0.51% 32
2022
Q4
$1.11M Buy
4,230
+388
+10% +$104K 0.51% 31
2022
Q3
$866K Buy
3,842
+469
+14% +$114K 0.41% 33
2022
Q2
$821K Sell
3,373
-113
-3% -$27.7K 0.38% 35
2022
Q1
$843K Buy
+3,486
New +$801K 0.3% 38

Other funds holding AMGN

Fairfield Financial Advisors's AMGN Position: Q2 2026 in Review

Fairfield Financial Advisors reduced its Amgen (AMGN) stake by 8% in Q2 2026, selling an estimated $141K and leaving 4,758 shares worth $1.72M. The position accounts for 0.68% of the portfolio, ranked #32.

Fairfield Financial Advisors first reported a position in AMGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.67M in Q3 2024. 3,149 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Fairfield Financial Advisors held 4,758 shares of Amgen worth $1.72M as of Q2 2026.
  • Fairfield Financial Advisors sold 413 Amgen shares in Q2 2026, an estimated $141K.
  • Amgen made up 0.68% of Fairfield Financial Advisors's portfolio in Q2 2026, its #32 holding.
  • Fairfield Financial Advisors first reported a position in Amgen in Q1 2022 and has held it in 17 quarters since.
  • Fairfield Financial Advisors's Amgen position peaked at $2.67M in Q3 2024.
  • 3,149 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Fairfield Financial Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.